XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segment information | 6 Months Ended
--- | ---
Jul. 01, 2018
Segment Reporting [Abstract] |
Segment information | Note 14 — Segment information Following the Company's acquisition of Vascular Solutions, the Company commenced an integration program under which it is combining the Vascular Solutions' business with some of its legacy businesses. As a result, effective during the fourth quarter 2017, the Company realigned its operating segments. The changes to the operating segments were also made to reflect the manner in which the Company’s chief operating decision maker assesses business performance and allocates resources. The Company now has the following seven reportable segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, Middle East and Africa ("EMEA"), Asia and Original Equipment and Development Services ("OEM"). In connection with the presentation of segment information, the Company will continue to present certain operating segments, which currently include the Interventional Urology North America, Respiratory North America and Latin America operating segments, in the “all other” category because they are not material for separate disclosure. All prior comparative periods presented have been restated to reflect these changes. The following tables present the Company’s segment results for the three and six months ended July 1, 2018 and July 2, 2017:
| Three Months Ended |  | Six Months Ended
| July 1, 2018 |  | July 2, 2017 |  | July 1, 2018 |  | July 2, 2017
| (Dollars in thousands) |  |
Vascular North America | $ | 80,062 |  |  | $ | 78,796 |  |  | $ | 163,110 |  |  | $ | 157,807 |
Interventional North America | 64,956 |  |  | 58,337 |  |  | 125,152 |  |  | 98,283 |
Anesthesia North America | 50,490 |  |  | 49,081 |  |  | 101,055 |  |  | 97,288 |
Surgical North America | 40,708 |  |  | 44,716 |  |  | 81,385 |  |  | 90,660 |
EMEA | 153,415 |  |  | 138,469 |  |  | 313,285 |  |  | 272,043 |
Asia | 72,413 |  |  | 65,998 |  |  | 130,657 |  |  | 116,166 |
OEM | 52,594 |  |  | 45,132 |  |  | 98,448 |  |  | 88,478 |
All other | 95,228 |  |  | 48,084 |  |  | 184,004 |  |  | 95,769 |
Net revenues | $ | 609,866 |  |  | $ | 528,613 |  |  | $ | 1,197,096 |  |  | $ | 1,016,494 |
| Three Months Ended |  | Six Months Ended
| July 1, 2018 |  | July 2, 2017 |  | July 1, 2018 |  | July 2, 2017
| (Dollars in thousands) |  | (Dollars in thousands)
Vascular North America | $ | 24,636 |  |  | $ | 18,472 |  |  | $ | 49,298 |  |  | $ | 36,762 |
Interventional North America | 16,510 |  |  | 8,815 |  |  | 30,630 |  |  | 780 |
Anesthesia North America | 14,716 |  |  | 20,056 |  |  | 32,049 |  |  | 33,360 |
Surgical North America | 17,055 |  |  | 17,287 |  |  | 31,803 |  |  | 33,667 |
EMEA | 26,535 |  |  | 23,594 |  |  | 58,305 |  |  | 44,904 |
Asia | 20,746 |  |  | 18,941 |  |  | 34,114 |  |  | 29,825 |
OEM | 13,552 |  |  | 10,337 |  |  | 22,568 |  |  | 19,458 |
All other | (25,602 | ) |  | 9,017 |  |  | (37,575 | ) |  | 18,344 |
Total segment operating profit (1) | 108,148 |  |  | 126,519 |  |  | 221,192 |  |  | 217,100 |
Unallocated expenses (2) | (74,658 | ) |  | (16,317 | ) |  | (100,859 | ) |  | (46,079 | )
Income from continuing operations before interest, loss on extinguishment of debt and taxes | $ | 33,490 |  |  | $ | 110,202 |  |  | $ | 120,333 |  |  | $ | 171,021 |
(1) | Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved.
(2) | Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.
The following table provides total net revenues by geographic region (based on the Company's selling location) for the three and six months ended July 1, 2018 and July 2, 2017:
| Three Months Ended |  | Six Months Ended
| July 1, 2018 |  | July 2, 2017 |  | July 1, 2018 |  | July 2, 2017
| (Dollars in thousands)
United States | $ | 356,468 |  |  | $ | 310,124 |  |  | $ | 700,825 |  |  | $ | 596,438 |
Europe | 168,879 |  |  | 144,393 |  |  | 340,200 |  |  | 285,415 |
Asia | 60,488 |  |  | 53,901 |  |  | 110,043 |  |  | 96,905 |
All other | 24,031 |  |  | 20,195 |  |  | 46,028 |  |  | 37,736 |
Net revenues | $ | 609,866 |  |  | $ | 528,613 |  |  | $ | 1,197,096 |  |  | $ | 1,016,494 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration